



BLA 761158/S-007

## SUPPLEMENT APPROVAL

GlaxoSmithKline Intellectual Property Development Ltd. England  
Attention: Kristina Vishnevetskaya, PharmD  
RAC, Manager, Global Regulatory Affairs  
1250 South Collegeville Road UP4400  
Collegeville, PA 19426

Dear Dr. Vishnevetskaya:

Please refer to your supplemental biologics license application (sBLA), dated and received October 8, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for Blenrep (belantamab mafodotin-blmf) for injection.

This Changes Being Effected supplemental new drug application provides for proposed modifications to the approved Blenrep (belantamab mafodotin-blmf) risk evaluation and mitigation strategy (REMS).

We have completed our review of this supplemental application, as amended. It is approved effective on the date of this letter.

### **RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS**

The REMS for Blenrep (belantamab mafodotin-blmf) was originally approved on August 5, 2020, and the most recent REMS modification was approved on November 20, 2020. The REMS consists of a communication plan, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consists of incorporation of the revised validity time frame of authorization for patients to receive their next scheduled dose of Blenrep based on their ophthalmic examination date in the REMS Document; allowing patients to provide verbal acknowledgement to enroll into the Blenrep REMS in the Patient Enrollment Form; adding a data entry field for “dose ordered in mg/kg” and “actual dose administered” in the REMS Checklist; updates to the portal to improve visibility of patient status and treatment history, granting delegates access to the online portal, allowing prescribers to add or remove delegates online, and editorial revisions on the Eye Care Professional Consult Request Form, Patient Enrollment Form, REMS Checklist and Education Program for both Prescribers and Healthcare Settings and Website screenshots.

Your proposed modified REMS, submitted on October 8, 2021, amended and appended to this letter, is approved.

The timetable for submission of assessments of the REMS remains the same as that approved on August 5, 2020.

There are no changes to the REMS assessment plan described in our August 24, 2021 letter.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use, as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication;
- b) A determination of the implications of a change in the benefit-risk profile for the current REMS;
- c) *If the new indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of that last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. *If you are not proposing REMS modifications,* provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**BLA 761158 REMS ASSESSMENT METHODOLOGY  
(insert concise description of content in bold capital letters, e.g.,  
ASSESSMENT METHODOLOGY, PROTOCOL, SURVEY METHODOLOGIES,  
AUDIT PLAN, DRUG USE STUDY)**

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**BLA 761158 REMS ASSESSMENT**

*or*

**NEW SUPPLEMENT FOR BLA 761158/ S-000  
CHANGES BEING EFFECTED IN 30 DAYS  
PROPOSED MINOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR BLA 761158/ S-000  
PRIOR APPROVAL SUPPLEMENT  
PROPOSED MAJOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR BLA 761158/ S-000  
PRIOR APPROVAL SUPPLEMENT  
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING  
CHANGES SUBMITTED IN SUPPLEMENT XXX**

*or*

**NEW SUPPLEMENT (NEW INDICATION FOR USE)  
FOR BLA 761158/ S-000  
REMS ASSESSMENT  
PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISIONS FOR BLA 761158**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, or website screenshots are only in PDF format, they may be submitted as such, but Word format is preferred.

**SUBMISSION OF REMS DOCUMENT IN SPL FORMAT**

FDA can accept the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, as soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in SPL format using the FDA automated drug registration and listing system (eLIST).

For more information on submitting REMS in SPL format, please email [FDAREMSwebsite@fda.hhs.gov](mailto:FDAREMSwebsite@fda.hhs.gov).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions you may contact Felicia Diggs, Safety Regulatory Project Manager, at (240) 402-4932 or via email at [Felicia.Diggs@FDA.HHS.gov](mailto:Felicia.Diggs@FDA.HHS.gov).

Sincerely,

*{See appended electronic signature page}*

Shan Pradhan, MD  
Associate Director for Safety (acting)  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

ENCLOSURE:

- REMS

U.S. Food and Drug Administration  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

SHAN PRADHAN  
12/07/2021 12:29:48 PM